PRODUCTS

WE TARGET UNMET NEEDS IN THE COMPANION AND FOOD ANIMAL HEALTH AND WELLBEING SECTORS

PRODUCT FOCUSED PARADIGM

Our goal is to use modern synthetic biology and chemistry technologies to deliver novel, effective and safe bioactive molecules, which are nature inspired to target unmet needs in the companion and food animal health and wellbeing sectors. This entails overcoming the challenges of working with nature inspired molecules: they have complex structures that are difficult to modify selectively, and are often expensive and difficult to produce on a large scale.

Chalante’s discovery strategy, exemplified by the ongoing projects, is application of a palette of biological and chemical technologies, evaluated in parallel and applied in series according to the project requirements. The company exploits natural products and processed as leads for development of products that are both bioactive and potent. Project-specific cascades of tailored, predictive, phenotypical assays enable the most efficacious molecules to be identified for development independent of mechanism of action.

OUR TWO ACTIVE PROGRAMS

1. NOVEL PARASITICIDES FOR COMPANION ANIMALS

Parasite resistance is an issue in the companion animals, and Chalante is developing a new generation of parasiticide compounds to overcome resistance and to target a broad range of endoparasites at economically viable prices.

Chalante’s primary aim is to develop a novel resistance-breaking parasiticide for the prophylactic treatment of dog heartworm. The dog heartworm disease is caused by the filariasis worm Dirofilaria immitis and is a life-threatening condition in dogs. Existing treatments are increasingly subject to resistance, as the last products approved for this indication belong to the macrocyclic lactone class that has been on the market for more than three decades.

We are developing a series of agents that represent a distinct mechanism of action in this space, designed to be effective in killing macrocyclic lactone-resistant infective larvae of D. immitis. Our first product under development is a novel, monthly, chewable treatment for a dog heartworm prevention.

parallax background
 

2. RESISTANCE BREAKING PARASITICIDES FOR FOOD ANIMALS

The current agents used to protect food animals are losing effectiveness due to development of resistance and emergence of new parasites. Despite this, there are very few new products available that address this unmet need. Chalante has identified an effective treatment option and ongoing activities focus on the cost of goods and yield.

Chalante’s goal is to use a novel synthetic approach to develop an efficacious and cost-effective parasiticide for food animals. The first product under development is a novel injectable parasiticide to prevent or treat internal parasites including gastrointestinal nematodes and lungworms for cattle and other livestock, to battle the losses in meat productivity associated with these infections.

TENS OF BILLIONS OF POUNDS WORTH OF LIVESTOCK ARE LOST TO PARASITES AND DISEASES ANNUALLY


TECHNOLOGY PLATFORM

Chalante pursues development of innovative products that address major problems in the animal industry. Animal health innovation is progressively more difficult, as demonstrated by the age and limited number of modes of action in the parasiticide market.

Chalante’s discovery strategy, exemplified by the ongoing projects, is application of a palette of biological and chemical technologies, evaluated in parallel and applied in series according to the project requirements. The company exploits natural products and processed as leads for development of products that are both bioactive and potent.

Our goal is to use modern synthetic biology and chemistry technologies to deliver novel, effective and safe bioactive molecules, which are nature inspired to target unmet needs in the companion and food animal health and wellbeing sectors. This entails overcoming the challenges of working with nature inspired molecules : they have complex structures that are difficult to modify selectively, and are often expensive and difficult to produce on a large scale. Close collaboration with our innovation partners makes this possible.